The New England journal of medicine, 2022-02, Vol.386 (5), p.437-448
- Makker, Vicky
- Colombo, Nicoletta
- Casado Herráez, Antonio
- Santin, Alessandro D
- Colomba, Emeline
- Miller, David S
- Fujiwara, Keiichi
- Pignata, Sandro
- Baron-Hay, Sally
- Ray-Coquard, Isabelle
- Shapira-Frommer, Ronnie
- Ushijima, Kimio
- Sakata, Jun
- Yonemori, Kan
- Kim, Yong Man
- Guerra, Eva M
- Sanli, Ulus A
- McCormack, Mary M
- Smith, Alan D
- Keefe, Stephen
- Bird, Steven
- Dutta, Lea
- Orlowski, Robert J
- Lorusso, Domenica
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Makker, Vicky
- Colombo, Nicoletta
- Casado Herráez, Antonio
- Santin, Alessandro D
- Colomba, Emeline
- Miller, David S
- Fujiwara, Keiichi
- Pignata, Sandro
- Baron-Hay, Sally
- Ray-Coquard, Isabelle
- Shapira-Frommer, Ronnie
- Ushijima, Kimio
- Sakata, Jun
- Yonemori, Kan
- Kim, Yong Man
- Guerra, Eva M
- Sanli, Ulus A
- McCormack, Mary M
- Smith, Alan D
- Keefe, Stephen
- Bird, Steven
- Dutta, Lea
- Orlowski, Robert J
- Lorusso, Domenica
- Titel
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
- Ist Teil von
- The New England journal of medicine, 2022-02, Vol.386 (5), p.437-448
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Women with advanced endometrial cancer that progressed during platinum-containing therapy were randomly assigned to lenvatinib plus pembrolizumab or physician’s choice of chemotherapy (doxorubicin or paclitaxel). The median progression-free survival was 7.2 months with lenvatinib plus pembrolizumab and 3.8 months with chemotherapy; the median overall survival was 18.3 months and 11.4 months, respectively.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2108330Titel-ID: cdi_proquest_miscellaneous_2621657684
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized - administration & dosage, Antibodies, Monoclonal, Humanized - adverse effects, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Cancer, Cancer therapies, Chemotherapy, Confidence intervals, Doxorubicin, Endometrial cancer, Endometrial Neoplasms - drug therapy, Endometrial Neoplasms - mortality, Endometrium, Female, Gynecologic Oncology, Gynecology, Hematology, Humans, Immunotherapy, Middle Aged, Mismatch repair, Monoclonal antibodies, Obstetrics, Oncology, Oral administration, Paclitaxel, Patients, Pembrolizumab, Phenylurea Compounds - administration & dosage, Phenylurea Compounds - adverse effects, Platinum, Population, Quinolines - administration & dosage, Quinolines - adverse effects, Solid tumors, Survival, Survival Analysis, Targeted cancer therapy, Treatments in Oncology, Vascular endothelial growth factor